Lung Density Analysis vs ClearRead CT

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Lung Density Analysis

by 4DMedical

ClearRead CT

by RIVERAIN TECHNOLOGIES

AI Verdict

Tool A, IMBIO's Lung Density Analysis, specializes in quantitative analysis and 3D visualization of diffuse lung conditions such as COPD and emphysema. In contrast, Tool B, Riverain Technologies' ClearRead CT, focuses on enhancing pulmonary nodule detection and coronary artery calcification analysis. While both operate on chest CT scans, their primary clinical applications target distinct pathologies, making them adjacent rather than direct competitors.

Choose Lung Density Analysis if…

Choose IMBIO's Lung Density Analysis if your primary need is a comprehensive, quantitative assessment and 3D visualization of diffuse lung conditions such as COPD, emphysema, asthma, or BOS. This tool is particularly well-suited for detailed disease characterization, tracking progression, and generating patient-centered reports like LungMap for counseling and personalized management.

View Lung Density Analysis →

Choose ClearRead CT if…

Choose Riverain Technologies' ClearRead CT if your focus is on significantly improving the detection and characterization of pulmonary nodules, including solid, part-solid, and ground glass types, and for efficient coronary artery calcification (CAC) scoring. Its patented vessel suppression technology and automated nodule tracking are ideal for reducing reading times and enhancing diagnostic accuracy in lung cancer screening and cardiac risk assessment workflows.

View ClearRead CT →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Lung Density Analysis	ClearRead CT
Pricing	Unknown	Contact for pricing
Deployment	Unknown	On-premise (stand-alone server, virtual machine) and Cloud
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung Density Analysis

Tool A, Lung Density Analysis, explicitly mentions 'automated workflows and detailed reports' and 'Patient-centered LungMapu2122 report' with '3D visualization,' which suggests a strong focus on user experience and patient communication. Its broader range of deployment options, including AI marketplaces, also indicates greater flexibility and ease of integration into various clinical environments.

Clinical Value

ClearRead CT

Tool B, ClearRead CT, provides concrete metrics for its clinical impact, claiming 'up to 36% reduced reading time' and '29% reduction in missed actionable nodules.' These specific, quantifiable improvements in diagnostic accuracy and workflow efficiency demonstrate a strong clinical value proposition. While Tool A is validated for low-dose CT and offers advanced density analysis, Tool B's direct impact on nodule detection and reading efficiency is more explicitly stated.

Pricing & Value

Tie

Both tools state 'contact for pricing' and do not publicly disclose their pricing details. Without any transparent information on cost or specific value-for-money claims, it is impossible to differentiate between the two products in terms of pricing and overall value.

Enterprise Readiness

Lung Density Analysis

Tool A explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA) in place. While Tool B indicates it is 'likely' HIPAA compliant and operates with institutions like the VA, Tool A's direct affirmative statements provide greater assurance. Additionally, Tool A offers a wider array of deployment options, including integration with AI marketplaces, which suggests broader enterprise compatibility and scalability.

Innovation

ClearRead CT

Tool B, ClearRead CT, highlights its 'Patented Vessel Suppression (Clear Visual Intelligence)' and 'Automated Nodule Tracking and Comparison to Prior Exams,' which are significant innovations directly addressing challenges in nodule detection and longitudinal patient management. While Tool A features 'Imbio Noise Reduction Technology (NRT)' and 'Functional LDA,' the patented vessel suppression in Tool B offers a distinct technological advantage for improving diagnostic clarity.

Support & Docs

Tie

Both companies provide general information about customer support on their websites, including contact methods and mentions of manuals and resources. However, neither publicly offers specific details regarding support tiers, service level agreements (SLAs), or comprehensive documentation portals that would allow for a clear head-to-head comparison.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Lung Density Analysis	ClearRead CT
Tool Name	Lung Density Analysis	ClearRead CT
Company	IMBIO	RIVERAIN TECHNOLOGIES
Primary Lung Analysis Focus	Automated detection, visualization, and quantification of emphysema; Advanced density analysis for COPD, Asthma, BOS	Pulmonary Nodule Detection (solid, part-solid, ground glass); Nodule Characterization and Measurement; Automated Nodule Tracking and Comparison to Prior Exams
Cardiovascular Analysis Capability	Not specified	Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs)
Key Technology/Report	Imbio Noise Reduction Technology (NRT) for low dose scans; Patient-centered LungMapu2122 report	Patented Vessel Suppression (Clear Visual Intelligence)
Workflow/Efficiency Claims	Automated workflows	Reduced Reading Time (up to 36%); Improved Detection Accuracy (29% reduction in missed actionable nodules)

Videos

Demos, reviews, and walkthroughs featuring Lung Density Analysis and ClearRead CT.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing radiology workflows and EHR systems to minimize disruption and maximize efficiency?

IMBIO's Lung Density Analysis offers automated workflows and fully automated quantitative analysis and 3D visualization directly to PACS, supporting integration into various AI marketplaces and stand-alone web-based access. ClearRead CT is designed for seamless PACS integration and vendor-neutral processing, aiming to streamline radiology workflows and reduce reading times by up to 36%.

Given their distinct analytical focuses, for which specific clinical scenarios or patient populations is each tool best suited?

IMBIO's Lung Density Analysis is ideal for diagnosing and managing conditions like COPD, emphysema, asthma, and BOS, providing quantitative analysis and 3D visualization of lung density, including a LungMapu2122 report for smoking cessation counseling. ClearRead CT excels in pulmonary nodule detection, characterization, and tracking, as well as coronary artery calcification (CAC) scoring from ungated, non-contrast CTs, making it suitable for lung cancer screening and cardiac risk assessment.

What specific accuracy and performance metrics are available, particularly for challenging cases like low-dose CTs or differentiating nodules from vessels?

IMBIO's Lung Density Analysis is validated for low-dose CT scans in lung cancer screening and incorporates Imbio Noise Reduction Technology (NRT) to enhance analysis on such scans. ClearRead CT boasts improved detection accuracy with a 29% reduction in missed actionable nodules and utilizes patented Vessel Suppression (Clear Visual Intelligence) to enhance clarity and provide an unimpaired view of the chest.

What is the typical learning curve for physicians and technologists, and how quickly can a practice expect to see clinical and operational benefits?

While not explicitly detailed, IMBIO's automated workflows and direct PACS integration suggest a design aimed at minimizing user burden and quickly integrating into existing routines for rapid clinical and operational benefits. ClearRead CT's stated ability to reduce reading times by up to 36% and its seamless PACS integration imply a rapid operational benefit and a straightforward adoption process for users, contributing to quick time-to-value.

What considerations should be made for deploying these tools across multiple sites or a large healthcare system, particularly regarding scalability and data management?

IMBIO offers flexible deployment options including cloud-based, locally virtualized, and integration in PACS or AI marketplaces, which can support diverse IT infrastructures and scalable multi-site rollouts. ClearRead CT supports both on-premise (stand-alone server, virtual machine) and cloud deployment models, providing flexibility for different institutional IT infrastructures and scalability needs across multiple sites.